Cerus (CERS) Q2 2026 Earnings Report

The call conveyed predominantly positive momentum: double-digit product revenue growth, raised product and IFC guidance, consecutive quarters of positive adjusted EBITDA, meaningful debt refinancing benefits, regulatory progress (PMA submission and upcoming Phase 3 readout), and a clean quality audit. Counterbalancing items include a drop in gross margin (51.4% vs 55.2% prior year) driven by currency and inflationary pressures, reduced government contract revenue this quarter, modest operating cash use for inventory, and regulatory/penetration challenges in Asia-Pacific and for broader IFC adoption. On balance the positives (top-line growth, improving profitability measures, stronger balance sheet flexibility, and regulatory/clinical progress) outweigh the near-term headwinds.

The company raised full‑year 2026 product revenue guidance to $229–$231 million (up from $227–$231M), and raised IFC revenue guidance to $23–$25 million, implying total product revenue growth of ~11–12% year‑over‑year and IFC growth of roughly 40–50% for the year; Q2 product revenue was $57.4M (up 10% YoY) and H1 product revenue was $111.1M (up 16% vs. $95.7M), with Q2 IFC revenue ~$6.7M (≈20% reported increase vs. $5.6M, or ~40% ex‑$0.8M prior‑period deferred revenue) and 70% of IFC shipments in kit form (with essentially all sales expected to be kits in 2027). Management expects 2026 product gross margins in the low‑50% range (Q2 was 51.4% vs. 55.2% prior year), reiterated guidance for a third consecutive year of positive non‑GAAP adjusted EBITDA (Q2 adjusted EBITDA $3.0M, the ninth consecutive quarter positive) and line‑of‑sight to GAAP profitability, and noted financing improvements — a $30M term‑loan reduction, revolver flexibility and up to $3.5M annual interest expense savings — plus regulatory/clinical timing including possible INT200 PMA approval as early as H1 2027 and REDes Phase‑3 topline expected in Q4 2026.